title: HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
abstract: HPV infections have become a major problem in immunocompromised patients, particularly in HIV-positive subjects. HPV lesions are observed more frequently in the ano-genital area and rarely in different body areas, such as the skin and oral cavity. However, in HIV-positive subjects there is an increased risk of oral condylomas. We describe the case of an HIV-positive Nigerian young woman, who came to our notice due to the appearance of small labial and mouth mucous membrane lesions, related to HPV infection, as shown by a biopsy. These lesions were not evident in the genital area. After two years in which the patient no longer received therapy, there was a progressive reduction in CD4 count, associated with the development of the oral condylomas. Hence the patient began a new HAART combination, but after seven months, although a slight improvement emerged in the CD4 count with the disappearance of HIV-RNA, there has been no regression of oral condylomas.
authors.affiliation: Diagnosi e Terapia dell'Immunodeficienza Umana Acquisita, Dipartimento di Medicina Pubblica, Clinica e Preventiva, Seconda Universita degli Studi, Napoli, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Martini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Colella
authors.forename: Addolorata
authors.initials: A
authors.lastname: Masiello
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lanza
authors.forename: Raffaella
authors.initials: R
authors.lastname: Pisapia
authors.forename: Angela
authors.initials: A
authors.lastname: Cascone
authors.forename: Filomena
authors.initials: F
authors.lastname: Di Martino
authors.forename: Alberico
authors.initials: A
authors.lastname: Filippini
authors.forename: Pietro
authors.initials: P
authors.lastname: Filippini
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D052685:Alphapapillomavirus / Q000302:isolation & purification*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007558:Italy; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D061466:Lopinavir; D009061:Mouth Mucosa / Q000821:virology; D009549:Nigeria / Q000208:ethnology; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D030361:Papillomavirus Infections / Q000150:complications*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use; D011477:Sex Work; D013280:Stomatitis / Q000150:complications / Q000821:virology*; D000068698:Tenofovir; D016312:Treatment Refusal; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use; D000099227:Abacavir
chemical_list: D000225:Adenine; D019380:Anti-HIV Agents; D003841:Deoxycytidine; D015224:Dideoxynucleosides; D000068679:Emtricitabine; D019259:Lamivudine; D061466:Lopinavir; D063065:Organophosphonates; D011744:Pyrimidinones; D019438:Ritonavir; D000068698:Tenofovir; D015215:Zidovudine; D000099227:Abacavir